Table 3. Use of Helixor in Cancer Treatment: Clinical Reports Describing Therapeutic Endpointsa
|Reference Citation(s)||Type of Study||Type(s) of Cancer||No. of Patients: Enrolled; Treated; Controlb||Strongest Benefit Reportedc||Concurrent Therapyd||Level of Evidence Scoree|
|||Randomized trial||Breast, stages I–III||692; 192; 274||Improved survival||Yes||1iiA|
|||Randomized trial||Colorectal, metastatic||60; 20; 20||Improved mean survival||Yes||1iiA|
|No. = number.|
|aSee text and the NCI Dictionary of Cancer Terms for additional information and definition of terms.|
|bNumber of patients treated plus number of patients controlled may not equal number of patients enrolled; number of patients enrolled = number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated = number of enrolled patients who were administered the treatment being studied AND for whom results were reported; historical control subjects are not included in number of patients enrolled.|
|cStrongest evidence reported that the treatment under study has anticancer activity or otherwise improves the well-being of cancer patients.|
|dChemotherapy, radiation therapy, hormonal therapy, or cytokine therapy administered/allowed at the same time as mistletoe therapy.|
|eFor information about levels of evidence analysis and an explanation of the level of evidence scores, see Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine.|
- Gutsch J, Berger H, Scholz G, et al.: [Prospective study in radically operated breast cancer with polychemotherapy, Helixor® and untreated controls]. Dtsch Z Onkol 21: 94-101, 1988.
- Douwes FR, Wolfrum DI, Migeod F: [Results of a prospective randomized study: chemotherapy versus chemotherapy plus "biological response modifier" in metastasizing colorectal carcinoma]. Dtsch Z Onkol 18 (6): 155-64, 1986.